210 related articles for article (PubMed ID: 33278177)
21. The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen.
Taramasso L; Berruti M; Briano F; Di Biagio A
AIDS; 2020 May; 34(6):877-881. PubMed ID: 32271252
[TBL] [Abstract][Full Text] [Related]
22. Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens.
Raffi F; Esser S; Nunnari G; Pérez-Valero I; Waters L
HIV Med; 2016 Oct; 17 Suppl 5():3-16. PubMed ID: 27714978
[TBL] [Abstract][Full Text] [Related]
23. Are New Antiretroviral Treatments Increasing the Risk of Weight Gain?
Shah S; Hindley L; Hill A
Drugs; 2021 Feb; 81(3):299-315. PubMed ID: 33400239
[TBL] [Abstract][Full Text] [Related]
24. Implications of weight gain with newer anti-retrovirals: 10-year predictions of cardiovascular disease and diabetes.
McCann K; Shah S; Hindley L; Hill A; Qavi A; Simmons B; Serenata C; Sokhela S; Venter WDF
AIDS; 2021 Aug; 35(10):1657-1665. PubMed ID: 33927086
[TBL] [Abstract][Full Text] [Related]
25. No evidence of rapid reversibility of tenofovir alafenamide and/or integrase strand transfer inhibitor-associated weight gain.
Verburgh ML; Wit FWNM; Boyd A; Reiss P; Van der Valk M;
AIDS; 2023 Oct; 37(12):1843-1850. PubMed ID: 37433218
[TBL] [Abstract][Full Text] [Related]
26. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance.
Acosta RK; Willkom M; Andreatta K; Liu H; Martin R; Parvangada A; Martin H; Collins S; White KL
J Acquir Immune Defic Syndr; 2020 Nov; 85(3):363-371. PubMed ID: 32701823
[TBL] [Abstract][Full Text] [Related]
27. Impact of Combination Antiretroviral Treatment on Liver Metabolic Health in HIV-Infected Persons.
Biały M; Czarnecki M; Inglot M
Viruses; 2023 Dec; 15(12):. PubMed ID: 38140673
[TBL] [Abstract][Full Text] [Related]
28. Effect of tenofovir alafenamide in combination with and without integrase inhibitors on weight gain, diabetes, and hypertensive disorders of pregnancy.
Nissim OA; Haney A; Lazenby GB
Pregnancy Hypertens; 2023 Dec; 34():47-52. PubMed ID: 37804587
[TBL] [Abstract][Full Text] [Related]
29. Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials.
Sax PE; Erlandson KM; Lake JE; Mccomsey GA; Orkin C; Esser S; Brown TT; Rockstroh JK; Wei X; Carter CC; Zhong L; Brainard DM; Melbourne K; Das M; Stellbrink HJ; Post FA; Waters L; Koethe JR
Clin Infect Dis; 2020 Sep; 71(6):1379-1389. PubMed ID: 31606734
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial.
Gallant JE; Daar ES; Raffi F; Brinson C; Ruane P; DeJesus E; Johnson M; Clumeck N; Osiyemi O; Ward D; Morales-Ramirez J; Yan M; Abram ME; Plummer A; Cheng AK; Rhee MS
Lancet HIV; 2016 Apr; 3(4):e158-65. PubMed ID: 27036991
[TBL] [Abstract][Full Text] [Related]
31. A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015-2017.
Gomez M; Seybold U; Roider J; Härter G; Bogner JR
Infection; 2019 Feb; 47(1):95-102. PubMed ID: 30269210
[TBL] [Abstract][Full Text] [Related]
32. Lack of an association between clinical INSTI-related body weight gain and direct interference with MC4 receptor (MC4R), a key central regulator of body weight.
McMahon C; Trevaskis JL; Carter C; Holsapple K; White K; Das M; Collins S; Martin H; Burns-Naas LA
PLoS One; 2020; 15(2):e0229617. PubMed ID: 32109250
[TBL] [Abstract][Full Text] [Related]
33. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
[TBL] [Abstract][Full Text] [Related]
34. A Review of the Efficacy and Safety of Genvoya® (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection.
Angione SA; Cherian SM; Özdener AE
J Pharm Pract; 2018 Apr; 31(2):216-221. PubMed ID: 28558493
[TBL] [Abstract][Full Text] [Related]
35. Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
Brown TT; Moser C; Currier JS; Ribaudo HJ; Rothenberg J; Kelesidis T; Yang O; Dubé MP; Murphy RL; Stein JH; McComsey GA
J Infect Dis; 2015 Oct; 212(8):1241-9. PubMed ID: 25948863
[TBL] [Abstract][Full Text] [Related]
36. Tenofovir disoproxil fumarate/emtricitabine is associated with a higher risk of hypocalcemia compared to abacavir/lamivudine - results from a German cohort study.
Noe S; Heldwein S; Jaeger H; Page M; Wolf E
Int J STD AIDS; 2019 Apr; 30(5):447-452. PubMed ID: 30630396
[TBL] [Abstract][Full Text] [Related]
37. Risk Factors for Weight Gain Following Switch to Integrase Inhibitor-Based Antiretroviral Therapy.
Lake JE; Wu K; Bares SH; Debroy P; Godfrey C; Koethe JR; McComsey GA; Palella FJ; Tassiopoulos K; Erlandson KM
Clin Infect Dis; 2020 Dec; 71(9):e471-e477. PubMed ID: 32099991
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials.
Tao X; Lu Y; Zhou Y; Zhang L; Chen Y
Int J Infect Dis; 2020 Apr; 93():108-117. PubMed ID: 31988012
[TBL] [Abstract][Full Text] [Related]
39. Short Communication: Resolution of Tenofovir Disoproxil Fumarate Induced Fanconi Syndrome with Switch to Tenofovir Alafenamide Fumarate in a HIV-1 and Hepatitis B Coinfected Patient.
Karris MY
AIDS Res Hum Retroviruses; 2017 Jul; 33(7):718-722. PubMed ID: 28403627
[TBL] [Abstract][Full Text] [Related]
40. The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single-tablet regimen in the expanding spectrum of fixed-dose combination therapy for HIV.
Stellbrink HJ; Lazzarin A; Woolley I; Llibre JM
HIV Med; 2020 Mar; 21 Suppl 1():3-16. PubMed ID: 32017355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]